Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 DM patients (with HbA1c level \< 8.5 %, BMI kg/m2 ≥ 25, SGPT ≤ 100 IU/L , creatinine ≤ 1.2 mg/dl) of both sexes,~* Aged between 40-50,~* Treated by monotherapy of pioglitazone or metformin.~Exclusion Criteria:~* Patients with diabetes secondary to another cause.~* Patients suffering from serious incurrent illness requiring systemic treatment.~* Patients suffering from any other infectious diseases.~* Patients with impaired kidney function (serum creatinine level more than 1.2mg/dl)~* Patients with impaired hepatic function (SGPT ≥ 100 IU/L).~* Patients with pulmonary insufficiency with hypoxaemia.~* Triglyceriadiamea (TG ≥ 150mg/dl).~* Bloodpressure \> 180 mmHg (Systolic) or \> 110 mmHg (diastolic).~* Positive history of drug or alcohol abuse.~* Pregnant women and willing to be pregnant shortly.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone (001 group) (Type: EXPERIMENTAL): The patients received pioglitazone hydrochloride tablet 30 mg (001 drug)once daily for first three months
- Metformin (002 group) (Type: EXPERIMENTAL): The patients received metformin hydrochloride tablet 850 mg (002 drug)once daily for next three months.

Based on this trial design, predict the completion outcome and termination type (if applicable).